7Maincent P, Le Verge R, Couvreur P, et al. Dispoition and oral bicavailbility of vinvamineloaded polyalkyl cyanoacrylate nanoparticles[J]. J Pharm Sci, 1986,75: 955.
8Odonnell PB, Mcginity JW. Prepation of micropsheres by the solvent evapodration technique[J]. Adv Drug Reliv rev, 1977,28:25.
9Damge C, Michd C,Aaprahanium, M, et al. New approach for oral administration of insulin with polyalkycyancacrylate nanoparticles as drug carrier[J]. Diabete, 1998, (37) :246.
10Keuter J,Alyautdin RN Kharkevuch DA, et al. Passage of peptide through the biood-brain barner with colloidal polymer paricles(nanoparticles) [J]. Brain Res, 1995,674:171.
1Muller RH, mader K, Gohla S. Solid lipid nanoparticles (SLN) for controlled drug delivery - a review of the state of the art [J]. Eur J Pharm Biopharm,2000,50( 1 ) :161-177
2Yang SC, Zhu JB, Lu Y,et al. Body distribution of camptothecin solid liid nanoparticles after oral adminidstration[J]. Pharm Res, 1999,16(5) :751-757
3MaaBen S,Schwarz C, Mehnen W,et al.Comparison of cytotoxicity beteen polyester nanoparticles and solid oipod nanoparticle (SLN)[J]. Proc Hit Symp Control Release Bioaxt Mater,1993,20:490-491
4Muller RH, Lucks JS. Arzneistofftrager aus festen Lipidteilchen,Feste Lipidnanospharen(SLN) [P]. Eur Pat, 0605497,1993-03-25
5Sakurai T,Iso T, Inoue H,et al. Effect of actarit combination therapy in patients with active rheumatoid arthritis resistant to gold agents[J]. Ryumachi, 2001,41(3) :635-645
6Nakamura H, Ueki Y, Sakito S, et al. Clinical effects of actarit in rheumatoid arthritis : improvement of early disease activity mediated by reduction of serum concentrations of nitric oxide [J]. Clin EXP Rheumatol,2000 ,18(4) :445-450
7Yang SC, Lu LF, Cai Y, et al. Body distribution in mice of intravenously injected camptothecin solid lipid nanoparticles and targeting effect on brain [J]. J Controlled Release, 1999,59 (3) :299-307
